Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead Sells 10,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $8.59, for a total transaction of $85,900.00. Following the transaction, the chief financial officer now owns 44,878 shares in the company, valued at $385,502.02. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Zynex Stock Performance

ZYXI opened at $8.00 on Tuesday. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. The firm has a market cap of $254.77 million, a PE ratio of 53.33 and a beta of 0.53. The business has a fifty day simple moving average of $8.10 and a 200-day simple moving average of $9.02. Zynex, Inc. has a fifty-two week low of $7.15 and a fifty-two week high of $13.77.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $49.97 million during the quarter, compared to analyst estimates of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. Zynex’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter last year, the company posted $0.10 EPS. As a group, equities analysts predict that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Zynex

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System purchased a new stake in shares of Zynex in the first quarter valued at $137,000. Investment Partners Asset Management Inc. acquired a new stake in Zynex during the 3rd quarter worth about $96,000. Hsbc Holdings PLC purchased a new position in Zynex during the 2nd quarter valued at about $113,000. Quest Partners LLC lifted its position in shares of Zynex by 646.7% in the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock worth $120,000 after purchasing an additional 11,195 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in Zynex by 56.4% in the 1st quarter. Principal Financial Group Inc. now owns 17,679 shares of the company’s stock valued at $219,000 after buying an additional 6,378 shares during the period. Institutional investors and hedge funds own 29.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Royal Bank of Canada lowered their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. HC Wainwright upped their price target on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, October 25th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.